The ground shifted today, and a lot of people here are pretending it didn’t happen.

CytoDyn didn’t drop a filler PR.
They announced something the trolls, shorts, and hired noise have feared for years:

Independent funding.
A real Expanded Access Program.
Actual patient access to leronlimab outside of trials.

Let’s break this down without the noise.

1. Independent funding is validation.

A private benefactor didn’t just “express support.”
They formally committed to fund access for TNBC patients who ran out of approved options.
People with real money don’t fund dead molecules.
This is belief backed by capital.

2. Real world data will arrive before Phase 2 matures.

Eligible TNBC patients will now receive leronlimab under FDA guidelines.
And the company wasn’t shy about the purpose:

Observe PD-L1 induction in real patients.

This is the mechanism behind long term survivors.
This is the Prime and Pair strategy.
Now it gets tested prospectively.

Not theory.
Not message board speculation.
Data. Incoming.

3. WEP Clinical is the CRO.

This is not some improvised side project.
WEP runs global EAPs for real biotechs.
They wouldn’t attach their name to vaporware.

4. The timing is not an accident.

Nader sentenced.
Baggage cleared.
Board finally free.

And days later:

Funding secured.
Infrastructure in place.
CRO engaged.
Protocol submitted to FDA.
Timeline set for March.

That’s not luck.
That’s execution.

5. The troll narrative collapsed today.

“No funding.”
Wrong.

“No benefactor.”
Wrong.

“No EAP.”
Wrong.

“No TNBC traction.”
Wrong.

“No PD-L1 effect.”
Wrong.

Mazzy and his little disciples are in full panic mode because everything they’ve screamed since 2021 just got invalidated in one morning.

Expect them to get louder.
It’s what happens when the script burns.

6. CYDY officially enters a new phase.

The board can now act without historical toxicity.
Trials move forward.
Partnerships watch from a safe distance.
Science applies pressure.
Data approaches.

And the truth does not care about anonymous basement dwellers recycling the same lines for four years.

Today is the start of a new chapter.

Price is noise.
Science is the signal.
And the signal just got a boost.

Stay sharp.
Stay focused.
Watch what comes next.